Digital transformation and product innovation may support pharmaceutical market performance, but research expenditure, product activity and realised sales are different measures. This study examines their reporting relationship in Kimia Farma and Phapros through a longitudinal documentary comparison of public reports covering 2021–2025. The detailed comparison uses 2024–2025 expense and sales information. Kimia Farma’s observed research expense increases from 45.52 to 47.34 billion rupiah after combining separately reported manufacturing and administrative lines, while revenue declines by 7.20 percent. Phapros’ manufacturing research expense decreases from 49.17 to 26.55 billion, while revenue rises by 26.34 percent. In Phapros, ethical and over the counter products account for the largest absolute sales increases, but the report does not isolate revenue generated by newly launched products. Digital narratives describe enabling infrastructure and customer channels rather than measured innovation returns. The contribution is a stage specific measurement framework that separates digital enablement, research input, product launch and commercial conversion. The findings do not identify a causal innovation effect or equate lower research expenditure with lower innovation capability.
Copyrights © 2026